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ABSTRACT
The regulation of microglial cell phenotype is a potential therapeutic intervention in neurodegener-
ative disease. Previously, we reported that transforming growth factor-b (TGF-b) levels inmesenchy-
mal stromal cells (MSCs) could be used as potential biological markers to predict the effectiveness
of autologous MSC therapy in patients with amyotrophic lateral sclerosis. However, the underlying
mechanism of TGF‐b in MSCs was not fully elucidated in determining the functional properties of
microglia. In this study, we aimed to clarify the role of TGF‐b that is involved in MSC effectiveness,
especially focusing on microglia functional properties that play a pivotal role in neuroinflammation.
We found that MSC-conditioned media (MSC-CM) inhibited proinflammatory cytokine expression,
restored alternative activatedmicroglia phenotypemarkers (fractalkine receptor,mannose receptor,
CD200 receptor), and enhanced phagocytosis in lipopolysaccharide (LPS)-stimulatedmicroglia. In ad-
dition, TGF-b inMSC-CMplayed amajor role in these effects by inhibiting the nuclear factor-kB path-
way and restoring the TGF-b pathway in LPS-stimulated microglia. Recombinant TGF-b also induced
similar effects to MSC-CM in LPS-stimulated microglia. Therefore, we propose that MSCs can modu-
late the functional properties of microglia via TGF-b secretion, switching them from a classically
activated phenotype to an inflammation-resolving phenotype. The latter role may be associated
with the inhibition of neuroinflammatory processes in neurodegenerative disorders. STEM CELLS
TRANSLATIONAL MEDICINE 2016;5:1538–1549
SIGNIFICANCE
The results of this study showed thatmicroglia functional propertiesmaybemodulateddependingon
the composition and quantity of mesenchymal stromal cell (MSC)-secreting factors. Transforming
growth factor (TGF)-b is proposed as a modulator of microglia functional properties among MSC-
secreting factors, and this study aligns with a previous clinical study by these same authors. TGF-b
releasing capacity could be an important factor enhancing the therapeutic efficacy ofMSCs in clinical
trials.
INTRODUCTION
Microglia are the resident innate immune cells
within the central nervous system (CNS) and par-
ticipate in normal CNS functional plasticity by
changing their morphology, surface receptor ex-
pression, and production of cytokines. Microglia
also play a role in the progression and resolution
of disease [1].Microglia display various activation
states induced by stimuli that arise from injured
neurons and surrounding glia, which is one aspect
of cell death mechanisms in neurodegenerative
diseases [2, 3]. In addition, microglia play a crucial
role in disease pathogenesis during neurode-
generative diseases such as Alzheimer’s disease
[4], Parkinson’s disease [5], multiple sclerosis
(MS) [6], and amyotrophic lateral sclerosis (ALS)
[7, 8]. Thesediseases share a commonmechanism:
neuroinflammation. As with macrophages, it has
been suggested that microglia can exhibit a classi-
cally activated phenotype (M1) or an alternatively
activated phenotype (M2) [2, 3].M1 exerts toxic ef-
fectsbysecretingproinflammatorycytokines—such
as tumornecrosis factor (TNF)-a, interleukin (IL)-1b,
IL-6, andnitric oxide (NO)—andplays a role as ama-
jor component of the neuroinflammatory response
following CNS injury. In contrast to M1, M2 is in-
volved in the maintenance of CNS homeostasis,
phagocytizing apoptotic bodies, releasing neurotro-
phic factors, and reducingproinflammatory cyto-
kines [9]. Markers such as fractalkine receptor
(CX3CR1), mannose receptor (CD206), and CD200
receptor (CD200R) detect the M2 phenotype [10],
andCX3CR1plays a critical role in controllingmicro-
glial neurotoxicity [11]. Complementary crosstalk
between constitutive CX3CL1 release on neurons
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andCX3CR1expression onmicroglia establishes a unique communi-
cation system to regulate the activation of microglia [11]. Consider-
ing that the persistent activation of microglia (M1-like phenotype)
has been demonstrated in chronic neurodegenerative diseases,
properly terminating M1 microglial activation and skewing their
functional phenotype toward a protective one might contribute to
neuronal protection, repair, and renewal in neurodegenerative dis-
eases [12]. Thus, the regulationofmicroglial cell phenotype couldbe
a potential therapeutic intervention.
Initially, mesenchymal stem or stromal cells (MSCs) attracted
public attention because of their multipotency. These cells are ca-
pable of differentiating intomultiplemesenchymal lineages, includ-
ing adipocytes, chondroblasts, and osteoblasts [13]. However,
recent preclinical data have demonstrated that exogenously ad-
ministeredMSCsexertmultifaceted therapeutic effects via immu-
nomodulation and trophic factor secretion rather than via cell
replacement, transdifferentiation, or fusion [14–16]. MSCs secrete
various cytokines andneurotrophic factors required for tissue repair
that are therapeutically useful, leading to improved neurological
function, such as neurogenesis, angiogenesis, and synaptogenesis
[17, 18]. On the basis of these MSC abilities, an accumulating body
of clinical trials has shown that MSCs are safe and may be an alter-
native therapeutic strategy for treating intractable neurological dis-
eases with unmet medical needs, including ALS, multiple sclerosis,
and other degenerative diseases [19–23].
Although numerous studies have reported the positive effect
of MSCs in various intractable neurological diseases, the mecha-
nism has not been elucidated. In addition, considering that there
are currently no U.S. Food and Drug Administration-approved Bi-
ologics License Applications for anyMSC-based products, despite
considerable interest and effort [24], it is important to clarify
which factors in MSCs are involved in therapeutic efficacy. Re-
cently, we proposed biological markers that are associated with
the efficacy of autologous MSCs administered intrathecally in
37 ALS patients [25]. We found that vascular endothelial growth
factor, angiogenin, and transforming growth factor-b (TGF-b) se-
cretionwere decreased inMSCs of nonresponder ALS patients. In
addition,MSCs of nonresponders are less effective than are those
of responders on motor function and survival time in mutant
SOD1G93A transgenic mice (ALS mice) when MSCs were trans-
planted into the cisterna magna, suggesting that these factors
could be used as potential biological markers to predict the effec-
tiveness of autologousMSC therapy. TGF-b is awell-knownpleio-
tropic cytokine that can transit microglia from an activated state
to a resting microglial phenotype associated with tissue repair
and CNS homeostasis, leading to the resolution of microglia-
mediated inflammation and wound healing [9]. However, there
are few reports clarifying the role ofMSCs secreting TGF-b on pri-
mary culturedmicroglia and focusing on themicroglial functional
phenotype. In the present study, our results show that TGF-b in
MSC-conditioned media (MSC-CM) plays a primary role in skew-
ing M1 toward inflammation-resolving M2 cells by inhibiting the
nuclear factor (NF)-kB pathway and restoring the TGF-b pathway
in lipopolysaccharide (LPS)-stimulated microglia.
MATERIALS AND METHODS
Primary Rat Microglial Culture and Identification
All proceduresonanimalswereperformed in accordancewith the
Hanyang University guidelines for the care and use of laboratory
animals (HY-IACUC- 2014-0092A). Primary microglial cells were
enriched in vitro using the shaking method described by Giulian
and Baker [26]. Briefly, 2-day-old Sprague Dawley rats were sac-
rificed and soaked in 75% ethanol for 1 minute. Cerebral hemi-
spheres were dissected out, following standard techniques and
anatomical landmarks, and then meninges were peeled off. The
hippocampus, basal ganglion, and olfactory bulb were carefully
removed with microsurgical instruments under a microscope,
and the remaining cortical tissuewasmincedwith a pair ofmicro-
surgical scissors. The shredded tissue was then incubated with
1mltrypsinand1mlphosphate-bufferedsaline (PBS) for15minutes
in a 37°C water bath with occasional swirling. After centrifuging
at 300 g for 3 minutes, the cells were plated into 75-cm2 flasks
that had been coated with poly-L-lysine. Mixed glial cells were
cultured in Dulbecco’s modified Eagle’s medium-high glucose
(DMEM-HG) containing 10% fetal bovine serum (FBS) and 0.1%
Glutamax at 37°C in 5% CO2 in air and 95% humidity. The culture
medium was replaced with 15 ml fresh growth medium after
24 hours. Subsequently, one half of the volume of culturemedium
was replaced with an equal volume of fresh growthmedium twice
per week. At the end of this period, stratification had been
reached, and themicroglial cells in the upper layer could be har-
vested. On day 11, flasks were placed on a MaxQ 2000 orbital
shaker (Thermo Fisher Scientific Life Sciences, Waltham, MA
USA, https://www.thermofisher.com) within the incubator and
shaken for 1 hour at 200 revolutions per minute (rpm). The me-
dium, containing detached microglia, was collected and centri-
fuged at 190 g for 8 minutes at 23°C. Cells were resuspended
with microglial complete culture medium (DMEM, 15% FBS, 0.1%
Glutamax, 5 mg/ml insulin, and 1% penicillin/streptomycin) and
transferred to poly-L-lysine-coated plates at a density of 2.53 105
cellsper milliliter. Flow cytometry analysis using fluorescein (FITC)
mouse antirat CD11b antibody (#554982; BD Pharmingen, San
Diego, CA, http://www.bdbiosciences.com) or FITC mouse IgG iso-
type (#553478, BD Pharmingen) confirmed the puremicroglia isola-
tion. In an immunofluorescence study, expression of the typical
microgliamarker (#ab128797, rabbit anti-CD11b, 1:200; Abcam,
Cambridge, UK, http://www.abcam.com) indicated greater than
99%of the isolated cellsweremicroglia. Glial fibrillary acidic pro-
tein (#Z0334, rabbit anti-GFAP, 1:200; Dako, Carpenteria, CA,
http://www.dako.com), an astrocyte marker, stained less than
1% of the cells. Tetramethylrhodamineisothiocyanate conju-
gated anti-rabbit IgG (#T2769; Thermo Fisher Scientific) and
Alexa-488 conjugated anti-rabbit IgG (#A11008, Invitrogen)
were used as secondary antibodies, respectively.
Rat MSC Conditioned Media and Drug Treatment in
Primary Cultured Microglia
Rat (Sprague Dawley)MSCswere purchased fromGibco (#S1601-
100; Thermo Fisher Scientific). MSC characterization was already
confirmed in themanufacture datasheet, and cells were cultured
as per the manufacturer’s indication. Briefly, cells were cultured
at a concentration of 43 103 cells per cm2 in DMEM-low glucose
with Glutamax-I and supplemented with 10% MSC-qualified FBS
and 5 mg/ml gentamicin (Thermo Fisher Scientific) at 37°C with
5% CO2. The medium was refreshed twice a week, and the cells
were subcultured before reaching 70%–80% confluence. MSCs
were used at their fourth passage.MSCs (53 105ml) were plated
into six-well plates (9.5 cm2). After 24 hours, the medium was
replaced, and the cells were incubated for another 48 hours, at
Noh, Lim, Oh et al. 1539
www.StemCellsTM.com ©AlphaMed Press 2016
the end of which time (MSC number; 1–23 106 ml) the medium
was collected and centrifuged at 1,500 rpm for 10 minutes at 4°C
and filtered through 0.22-mm filters (Merck Millipore, Billerica,
MA, http://www.emdmillipore.com) before use. The obtained
medium was defined and used as MSC-conditioned medium
(MSC-CM) in our study. For microglia activation, 100 ng/ml lipo-
polysaccharide (LPS; Sigma-Aldrich, St. Louis, MO, http://www.
sigmaaldrich.com) was added to the culture medium for 24, 48,
or 72 hours. LPS-stimulated microglia were treated for 24, 48,
or 72 hours with MSC-CM. TGF-b1 receptor (TGF-b1R) inhibi-
tor (SB505124; Sigma-Aldrich), CX3CL1 neutralizaing antibody
(ab#8021; Abcam), whose stocks were diluted in complete
medium, were mixed with MSC-CM. The recombinant TGF-b1
(PHG9024; Thermo Fisher Scientific) or recombinant CX3CL1
(400-26; PeproTech, Rocky Hill, NJ, https://www.cedarlanelabs.
com) were treated for 24 hours. Control samples were given
equivalent volumes of complete medium. Thus, the primary cul-
turedmicroglial cells were divided into the following nine groups:
control (group 1, in DMEM-HG containing 10% FBS), 100 ng/ml
LPS treatment for 24hours (group2),MSC-CMtreatment in group
2 (group 3), MSC-CM treatment with 2 mM TGF-b1R inhibitor in
group 2 (group 4), siMSC-CM (conditioned medium that was
obtained from MSCs transfected with TGF-b1 siRNA) treatment
in group 2 (group 5),MSC-CM treatmentwith 1mg/ml CX3CL1 an-
tibody in group 2 (group 6), MSC-CM treatment with 1 mg/ml
CX3CL1 antibody and 2 mM TGF-b1R inhibitor in group 2 (group
7), 24hoursof10ng/ml recombinant TGF-b1 (rTGF-b1) treatment
in group 2 (group 8), and 24 hours of 10 ng/ml recombinant CX3CL1
treatment in group 2 (group 9). To determine the concentration-
dependent effect of rTGF-b1onmicroglia functional phenotype,
we treated 300, 700, 1,000, and 1,400 pg/ml of rTGF-b in LPS-
stimulated microglia.
TGF-b1 siRNA Transfection to MSC
MSCs were stably transfected with FlexiTube small interfering
RNA (siRNA) for rat TGF-b1 (NM_021578) or negative-control
siRNA (#SI03650318) using HiPerFect Transfection Reagent
(#301705; Qiagen, Hilden, Germany, https://www.qiagen.com).
The siRNA transfection was performed in serum-freemedium, fol-
lowing the manufacturer’s instruction. The most efficient target
sequence for RNA interference was selected from among four
sequences provided by Qiagen (#SI02044987, #SI02044994,
#SI02045008, and #SI04717951). All siRNAswere tested for mRNA
knockdowns by real-time polymerase chain reaction (PCR).
Quantitative Real-Time PCR
The microglia cells were detached to quantify gene expression
after drug treatment. Total RNA was extracted using TRIzol re-
agent (Thermo Fisher Scientific) and evaluated with a Nano-
drop (ND-2000; ThermoFisher Scientific). cDNAwas synthesized
by using an EcoDry cDNA kit (Clontech, Mountain View, CA,
http://www.clontech.com). We analyzed TNF-a (PPR06411F;
Qiagen), IL-1b (PPR06480B;Qiagen), IL-6 (PPR06483B;Qiagen),
inducible nitric oxide (iNOS) (PPR44835A; Qiagen), CX3CR1
(PPR06709A; Qiagen), CD206 (Mannose receptor: PPR65066A;
Qiagen), TGF-b1 (pPPR06430B; Qiagen), and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) (PPR06557B; Qiagen).
cDNA was amplified using Power SYBR Green PCR Master Mix
with primers in an Applied Biosystems Step One Plus system
(Thermo Fisher Scientific) at 95°C for 10 minutes, followed by
40 cycles of 15 seconds at 95°C and 1minute at 60°C. A melting
curve was generated to examine the specificity of the amplifi-
cation. The relative quantity levels were calculated with the
22DD Ct method using GAPDH as the interval standard control.
The reported results are based on three independent experi-
ments on separate batches of cells.
Nitrate Assay
Nitrate levels were measured using a nitrate assay kit (R&D Sys-
tems, Minneapolis, MN, https://www.rndsystems.com). The
nitrate level in the supernatant was measured and analyzed
according to the manufacturer’s instruction.
Flow Cytometry Analysis
AfterMSC-CM treatment of LPS-stimulatedmicroglia for 72 hours,
themicrogliawere immune-labeledbyusing antibodies against the
surface proteins CD86, CX3CR1, CD206, and CD200R. Indirect im-
munofluorescence flow cytometry was performed using the fol-
lowing antibodies: rabbit anti-CD86 (1:100, #ab53004, Abcam),
rabbit anti-CX3CR1 antibody (1:100, ab#8021; Abcam), and rabbit
anti-CD206 antibody (1:100, #ab64693; Abcam), and mouse anti-
CD200R-PE (1:100, #ab34135; Abcam). The microglia cells were
washed with Stain buffer (BD Pharmingen) and incubated with
primary antibody for 30 minutes at RT, washed with calcium-
magnesium-free [PBS(2)], resuspended, and fixed with 1% para-
formaldehyde (Wako, Osaka, Japan, http://www.wako-chem.co.
jp) inPBS(2).Afterprimarystaining, themicroglia cellswerewashed
with stain buffer and stained with anti-rabbit Alexa 488-conjugated
secondary antibodies (#A11008, Thermo Fisher Scientific). The
expression ratio of CD86, CX3CR1, CD206, and CD200R was cal-
culated with the fluorescent intensity of each fluorochrome
[27]. All data were collected on a FACS Canto II flow cytometer
(BD Biosciences) and were analyzed with FACS Diva and FlowJo
software (BD Biosciences).
Immunocytochemistry
iNOS, CX3CR1, and CD206 were used as microglia phenotype
markers. Iba-1 was used as a microglia marker. Microglia were
seeded on glass coverslips in 24-well plates and cultured with
LPS for 24 hours. Cells were washed with PBS and cultured with
PBS or MSC-CM for 72 hours and then fixed in 4% formaldehyde
and permeabilized with 0.1% Triton X-100 for 5 minutes. Indirect
immunofluorescence was performed using the following anti-
bodies: rabbit anti-iNOS antibody (#sc-8310,1:200; Santa Cruz
Biotechnology, Santa Cruz, CA, http://www.scbt.com), rabbit
anti-CX3CR1 antibody (ab#8021, 1:200; Abcam), rabbit anti-
CD206 antibody (#ab64693, 1:200, Abcam), and mouse anti-
Iba-1 antibody (#019-19741, 1:200; Wako). Cells were incubated
in primary antibodies diluted in 0.1% Triton-X 100 in PBS contain-
ing 5% normal goat serum at 4°C overnight. After rinsing three
times with PBS(2) for 5 minutes, anti-rabbit Alexa 546- and
anti-mouse Alexa 488-conjugated secondary antibodies (Thermo
Fisher Scientific) were used for detection. Nuclei were counter-
stained with 49,6-diamidino-2-phenylindole (DAPI; Sigma-Aldrich).
Cells without the addition of primary antibody served as nega-
tive controls. Fluorescent images were taken with a confocal
microscope (TCS SP5; Leica, Wetzlar, Germany, http://www.
leica-microsystems.com).
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Phagocytosis Assay
For the quantification of microglial phagocytosis, primary micro-
glia were seeded at a concentration of 33 105 on 35-mm glass-
bottomcell culturedishes as a control. Themicrogliawere treated
with 100 ng/ml LPS for 24 hours (LPS), and the LPS group was in-
cubated in the presence or absence of the same concentration of
MSC-CM for 24, 48, and 72 hours (LPS + MSC-CM). At the end of
each treatment, cells were incubatedwith 10ml of red-dyed fluo-
resbrite microspheres red fluorescent latex beads (2 mm; Sigma-
Aldrich) for 30 minutes at 37°C. Phagocytic activity was then
stopped by adding 2ml ice-cold PBS. The cells werewashed twice
with ice-cold PBS, fixed, and counterstainedwithDAPI. Cells were
analyzed by confocal microscopy (TCS SP5; Leica). The number of
phagocytosed beads per cell indicated phagocytic activity.
Western Blot
Cells were washed twice in cold PBS (Biochrom, Berlin, Germany,
http://www.biochrom.de) and incubated for 10minutes on ice in
radioimmunoprecipitation assay buffer. Protein concentration of
the cell lysates was determined using a Bio-Rad protein assay kit
(Bio-Rad, Hercules, CA, http://www.bio-rad.com). Samples con-
taining equal amounts (50 mg) of protein were resolved by 10%
sodium dodecyl sulfate-polyacrylamide gel electrophoresis and
transferred to nitrocellulose membranes (Amersham Pharmacia
Biotech,Piscataway,NJ,http://www.gelifesciences.com).Themem-
branes were blocked with 5% skim milk and then incubated with
specific primary antibodies. We used antibodies against rabbit
anti-CX3CR1(ab#8021, 1:1000; Abcam), mouse antip-IkB (SC-8404;
SantaCruz), and rabbit anti-IkB (#SC-371, 1:1000; SantaCruz), rabbit
antip-Smad2/3 (#8828, 1:1000; Cell Signaling, Danvers, MA, http://
www.cellsignal.com), Smad2/3 (#8685, 1:1000; Cell Signaling),
and GAPDH (SC-25778, 1:1,000; Santa Cruz). The membranes were
washed with Tris-buffered saline containing 0.05% Tween-20 and
then processed using a horseradish peroxidase (HRP)-conjugated
secondary anti-rabbit or -mouse antibody (Amersham Pharmacia
Biotech) followed by enhanced chemiluminescence (ECL) detection
(Amersham Pharmacia Biotech). The Western blot results were
quantified with an image analyzer (Quantity One-4,2,0; Bio-Rad)
andnormalized toGAPDH immunostaining, as previously described
[28]. The reported results are based on three independent experi-
ments on separate batches of cells.
Enzyme-Linked Immunosorbent Assays Analysis and
Lactate Dehydrogenase Assay
Forquantification of TGF-b1andCX3CL1 levels in the supernatant
of all groups and inMSC-CM,weperformedenzyme-linked immu-
nosorbent assays (ELISA) using commercially available kits on su-
pernatants derived fromeach culture condition. Rat TGF-b1ELISA
(R&D Systems) and rat CX3CL1 ELISA kits (Abcam) were used
according to themanufacturer’s instructions. Lactate dehydroge-
nase (LDH) assay (#TB163; Promega, Madison, WI, http://www.
promega.com) was performed according to the manufacturer’s
instructions. The reported results are based on three indepen-
dent experiments on separate batches of cells.
Statistical Analysis
The data are presented as the means 6 SEM. The statistical
significance of the differences between the groups was
assessed using Student’s t test and one-way analysis of
variance using GraphPad Prism Version 5.0 software for Mac
OS X (GraphPad Software, San Diego, CA, http://www.graphpad.
com). Bonferroni’s post hoc analysiswas performedwhen p values
were,.05.
RESULTS
LPS Increased Proinflammatory Cytokines in Primary
Cultured Microglia
After microglia culture, we confirmed that 99% of cells were
CD11b-positive by flow cytometry. By immunofluorescence, ex-
pression of the typical microglia marker (CD11b) was presented
in greater than 99% of the isolated cells. GFAP, an astrocyte
marker, was observed in less than 1% of the cells (Fig. 1A). To ex-
amine the effect of LPS in primary cultured microglia, we applied
100 ng of LPS for 24 hours, 48 hours, and 72 hours. LPS increased
proinflammatory cytokine expression such as TNF-a, IL-1b, IL-6,
and iNOS in primary culturedmicroglia. LPS treatment for 24 hours
was sufficient to induce cytokine expression. In line with iNOS ex-
pression, nitrate accumulated gradually in culture supernatant in a
time-dependent manner (Fig. 1B). Thus, we confirmed that 24
hours LPS (100 ng/ml) could induce a sufficient inflammatory reac-
tion in microglia.
InflammatoryReaction in LPS-StimulatedMicrogliaWas
Suppressed by MSC-CM
To determine the role of soluble factors that are secreted by
MSCs, we collected the supernatant (MSC-CM) after 48 hours
of MSC culture. The cell number was 1–2 3 106 cell/ml at that
time. MSC-CM was applied for 24, 48, and 72 hours to LPS-
stimulated microglia, and mRNA expression was analyzed after
MSC treatment. As shown in Figure 2A, LPS significantly increased
TNF-a, IL-1b, IL-6, and iNOSmRNA levels, and nitrate secretion in
microglia. MSC-CM completely inhibited the inflammatory reac-
tion of LPS-stimulated microglia in a time-dependent manner. By
immunofluorescence, we confirmed the effect of MSC-CM on
iNOS expression in LPS-stimulated microglia (Fig. 2B). MSC-CM
enhanced phagocytosis in LPS-stimulated microglia (Fig. 2C), in
accordance with a previous study [29].
MSC-CM Rescues Both CX3CR1 and CD206 Expression,
Which Were Reduced in LPS-Stimulated Microglia
Microglia phenotypes are associated with effector function, and
the transition fromM1toM2phenotype reflects the resolution of
inflammation. To investigate the effect of MSC-CM on microglia
phenotype, we used flow cytometry analysis, immunofluores-
cence, and quantitative PCR. As is shown in Figure 3, in flow
cytometry analysis, we found that treatment with MSC-CM re-
stored M2 markers such as CX3CR1, CD206, and CD200R, which
were reduced by LPSwhileMSC-CM inhibited CD86 (M1marker),
showing that the M2:M1 mean fluorescence intensity ratio
(CX3CR1, CD2006, CD200R: CD86) was restored by MSC-CM in
LPS-stimulated microglia. In addition, the microglia apoptosis in
all groups was not detected in LDH assay (supplemental online
Fig. 1). By immunofluorescence, the reduction of CX3CR1 and
CD206 was observed mainly in microglial process of LPS-stimulated
microglia,whichwas rescuedbyMSC-CM.ThemRNA levelsof both
CX3CR1 and CD206 were also rescued in an incubation time-
dependent manner.
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TGF-b in MSC-CM Plays a Main Role in Inhibition of
Proinflammatory Cytokine Expression and Restoration
of CX3CR1 Expression in LPS-Stimulated Microglia
Previously, CX3CL1 was suggested to be a direct modulatory
factor that can transition microglia to the M2 phenotype
[29]. TGF-b is an anti-inflammatory cytokine that can resolve
inflammatory reactions in microglia. We reported that TGF-b
might be involved in MSC efficacy when MSCs were adminis-
tered intrathecally in ALS patients [25]. Thus, we investigated
the role of TGF-b and CX3CL1 in LPS-stimulated microglia, fo-
cusing on CX3CR1 and proinflammatory cytokine expression.
As is shown in Figure 4, LPS increased proinflammatory cyto-
kine expression, and MSC-CM inhibited these inflammatory
reactions with restoration of CX3CR1 expression in LPS-stimulated
microglia. When TGF-bR inhibitor and CX3CL1 antibody were
added to MSC-CM to investigate the role of soluble TGF-b
and CX3CL1on MSC-CM effect, CX3CL1 antibody treatment
did not abolish the effect of MSC-CM, whereas TGF-bR inhib-
itor did. In addition, CX3CL1 antibody neutralized CX3CL1 com-
pletely in MSC-CM (supplemental online Figs. 2, 3). TGF-bR
inhibitor alone did not affect CX3CR1, TNF-a, IL-1b, and IL-6
mRNA levels (data not shown). Furthermore, we transfected
TGF-b siRNA into MSCs (siMSC) and obtained the conditioned
medium from siMSC (siMSC-CM). More than 50% of TGF-b ex-
pression and secretion was reduced in siMSC (supplemental
online Fig. 4) and siMCS-CM exhibited a blunted inhibitory ef-
fect on inflammatory response in LPS-stimulated microglia.
These results suggest that the TGF-b signaling pathway
may be involved in the effect of MSC-CM on LPS-stimulated
microglia. To investigate whether double blocking of both
TGF-b and CX3CL1 completely abolished the effect of MSC-
CM on LPS-stimulated microglia, we added a combination
treatment of both TGF-bR inhibitor and CX3CL1 antibody in
MSC-CM. As is shown in Figure 5, the double blocking did
not show any difference from the results of TGF-bR inhibitor
alone, suggesting that TGF-b alone in MSC-CM inhibits proin-
flammatory cytokine expression and rescues CX3CR1 expres-
sion, similar to the results shown in Figure 4.
Recombinant TGF-bMimics MSC-CM on LPS-
Stimulated Microglia
Confirming that TGF-bplays amajor role in the effects ofMSC-CM
on LPS-stimulated microglia, we investigated whether recombi-
nant TGF-b (rTGF-b) had similar effects as MSC-CM. Tomaximize
the effect of rTGF-b and to match the concentration of rCX3CL1
(10 ng/ml) that was used in a previous study [29], a high concen-
tration (10 ng/ml) of rTGF-b was used. As is shown in Figure 6,
rTGF-b suppressed the expression of all proinflammatory cyto-
kines in LPS-stimulated microglia, similar to the effect of MSC-
CM. Interestingly, rCX3CL1 (10 ng/ml) inhibited IL-1b and iNOS
expression and restored CX3CR1 expression but did not affect
TNF-a and IL-6 expression [29]. Furthermore, we confirmed that
rTGF-b mimics MSC-CM effect in a concentration-dependent
manner (supplemental online Fig. 5). These results and those
of a previous study [29] suggest that CX3CL1 and TGF-b both reg-
ulate microglia effector function in LPS-stimulated microglia,
depending on the composition and concentration of factors that
MSCs secrete.
Figure1. Lipopolysaccharide (LPS)-induced inflammatory reaction inprimary culturedmicroglia. (A):Characteristics of primary culturedmicro-
glia by flow cytometry and immunocytochemistry. The primary cultured cells were 99.8% CD11b positive, confirming pure microglia isolation.
Glial fibrillary acidic protein, an astrocytemarker, was observed in less than 1% of the cells. (B): LPS, 100 ng/ml, was applied to primary cultured
microglia for 24, 48, and 72 hours. LPS increased mRNA expression of TNF-a, IL-1b, IL-6, and inducible nitric oxide at all time points. Nitrate
concentration gradually increased with LPS treatment duration. The data are means 6 SEM of three independent experiments. ppp, p ,
.001 in comparison with control and 0 hour. Abbreviations: DAPI, 49,6-diamidino-2-phenylindole; FSC-A, forward scatter; GFAP, glial fibrillary
acidic protein; hr, hour; IL, interleukin; RQ, relative quantity; SSC-A, side scatter; TNF, tumor necrosis factor.
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MSC-CM Inhibits the NF-kB Pathway and Rescues
CX3CR1 Expression via the TGF-b Signaling Pathway in
LPS-Stimulated Microglia
As is shown inFigure7,LPS increasedp-IkBand reducedp-smad2/3
and CX3CR1 expression. MSC-CM normalized these alterations
in LPS-stimulated microglia. A TGF-bR inhibitor—which alone
did not affect CX3CR1, p-IkB, and p-smad2/3 expression levels—
abolished the effects of MSC-CM, suggesting that MSC-CM
inhibited the NF-kB pathway and rescued CX3CR1 expression
via the TGF-b pathway in LPS-stimulated microglia. In addition,
these results suggest that TGF-b in MSC-CM plays a central role
in the inhibition of proinflammatory cytokine expression and
the rescue of CX3CR1 expression in LPS-stimulated microglia.
DISCUSSION
Considering that neuroinflammation is one of the most striking
hallmarks of neurodegenerative disease and that microglia play
pivotal roles in neuroinflammation, it is important to investigate
whether MSCs can modulate microglial functional phenotypes
and which factors produced by MSCs are responsible. We
reported that soluble factors such as prostaglandin E2,
indoleamine-2,3 dioxygenase, and TGF-b secreted by MSCs have
immunomodulatory functions, which may resolve inflammatory
reactions and lead to the prevention of neuronal damage [30].
In the present study, our results suggest that TGF-b secreted
by MSCs plays a central role on skewing the classically activated
M1 phenotype toward a protective M2 phenotype by inhibiting
the NF-kB pathway and leading to a reduction of proinflamma-
tory cytokine expression in LPS-stimulated microglia. Previously,
we proposed that TGF-bmight be a biological marker associated
with the efficacy of MSCs administered intrathecally to ALS pa-
tients [25]. Interestingly, the TGF-b concentration in microglia
culture medium was similar to the cerebrospinal fluid (CSF) of
ALS patients (TGF-b: 600–800 pg/ml) before intrathecal MSCs in-
jection (supplemental online Fig. 2). In addition, the TGF-b concen-
tration (1744.9 6 95.8 pg/ml) in the LPS + MSC-CM group was
a little higher than was the CSF of ALS patients at 1 month after
intrathecal 1 3 106 MSC injection (TGF-b: 1200–1300 pg/ml)
(supplemental online Fig. 3). Thus, our in vitro result seems to ad-
equately reflect our phase I clinical trial results that intrathecal
MSC injection increased TGF-b concentration in CSF [23]. With
all results taken together, we speculate that TGF-b may be one
Figure 2. MSC-CMsuppressed the inflammatory reaction and enhanced phagocytosis in LPS-stimulatedmicroglia. (A): Todetermine the effect
of MSC-CM on the level of cytokines in LPS-stimulated microglia, we applied MSC-CM for 24, 48, and 72 hours to LPS-stimulated microglia. LPS
increased mRNA expression of TNF-a, IL-1b, IL-6, and iNOS, and nitrate secretion in LPS-stimulated microglia, whereas MSC-CM inhibited the
inflammatory reaction. (B): Immunostaining shows that MSC-CM significantly suppressed iNOS expression in LPS-stimulated microglia. The
microglia and nuclei were stainedwith Iba-1 andDAPI, respectively. (C): LPS-stimulatedmicroglia ingestedmore latex beads than did untreated
controls, and the phagocytic activity of microglia was significantly enhanced when the MSC-CM was applied to LPS-stimulated microglia fol-
lowing LPS treatment. The data aremeans6 SEM of three independent experiments. p, p, .05; pp, p, .01; ppp, p, .001; in comparison with
control. x,p, .05;xx,p, .05;xxx,p, .001; in comparisonwith LPS.Abbreviations: CON, control;DAPI, 49,6-diamidino-2-phenylindole; hr, hour;
iNOS, inducible nitric oxide; IL, interleukin; LPS, lipopolysaccharide; MSC-CM,mesenchymal stromal cell-conditionedmedia; RQ, relative quan-
tity; TNF, tumor necrosis factor.
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Figure 3. MSC-CM restored CX3CR1, CD206, and CD200R expression in LPS-stimulated microglia. To investigate the effect of MSC-CM on the
expression of CD86, CX3CR1, CD206, and CD200R in LPS-stimulated microglia, we performed flow cytometry. (A):Microglia were treated with
LPS for 24hours andMSC-CMwas incubated for 72hours. The isotype controlwas indicatedas gray color. Control group (red), LPS group (green),
and LPS +MSC-CM (blue)were indicated, respectively. The table box beside the diagram indicates the percentage of positive cells in each group.
(B):Rather than divide thismicroglia population further by imposing strict boundaries on a continuous expression pattern, we then determined
MFI of the entire remaining population for each marker, and we calculated theM2:M1MFI ratio (CX3CR1, CD206, or CD200R/CD86). MSC-CM
(Figure legend continues on next page.)
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of the main factors regulating microglial function and determin-
ing the efficacy of MSCs in ALS and other neurodegenerative dis-
eases involving microglia.
On the basis of a previous study showing that CX3CL1 could
shapemicroglia effector functions in themurinemicroglia cell line
N9 [29], we investigated the role of CX3CL1 and TGF-b in primary
cultured microglia following LPS treatment. In contrast to the re-
sult of aprevious study thatusedmouseMSCsandN9cell line, our
results showed that a CX3CL1 neutralizing antibody did not block
the phenotype transition effect of MSC-CM in LPS-stimulated
microglia. In addition, regardless of the presence of CX3CL1 in
MSCs, TGF-b alone sufficiently modulated microglia effector
function. On the other hand, recombinant CX3CL1 (10 ng/ml)
could shape microglia effector function, in agreement with the
previous study [29]. MSCs can secret different composition and
capacity of soluble factors, depending on microenvironment
Figure 4. TGF-bmediates the effect ofMSC-CMon LPS-stimulatedmicroglia. To determinewhich soluble factorwas involved in the effect of
MSC-CM on LPS-stimulated microglia, we treated LPS-stimulatedmicroglia with MSC-CM + a TGF-bR inhibitor (A), a CX3CL1 antibody (B), or
siMSC-CM (siMSC-CM indicates conditionedmedium thatwas obtained fromTGF-b siRNA-transfectedMSCs) (C). LPS increased TNF-a, IL-1b,
IL-6, and iNOS mRNA levels, and MSC-CM inhibited the increased cytokines and led to CX3CR1 restoration. TGF-b inhibition abolished the
effect ofMSC-CMon LPS-stimulatedmicroglia,whereas CX3CL1 antibodydid not. siMSC-CMdidnot affect LPS-stimulatedmicroglia. Thedata
aremeans6 SEMof three independent experiments. p, p, .01; pp, p, .001; in comparisonwith control (CON). x, p, .05; xx, p, .01; xxx,
p, .001; in comparison with LPS. †, p, .05; ††, p, .01; †††, p, .001; in comparison with two groups (LPS +MSC-CM vs. LPS +MSC-CM +
antibody/inhibitor or siMSC-CM). Abbreviations: CON, control; iNOS, inducible nitric oxide; IL, interleukin; LPS, lipopolysaccharide; MSC-
CM,mesenchymal stromal cell-conditionedmedia; n.s., not significant; RQ, relative quantity; TGF, transforming growth factor; TNF, tumor
necrosis factor.
(Figure legend continued from previous page.)
restored CX3CR1, CD206, andCD200RMFI,whereas it inhibited the CD86 in LPS-stimulatedmicroglia, showing the normalization ofM2:M1MFI
ratio. (C): Immunofluorescence results showed a similar pattern with flow cytometry analysis. Microglia was stained with Iba-1 and DAPI, re-
spectively. (D):MSC-CMrestoredmRNAexpression of CX3CR1 andCD206 in LPS-stimulatedmicroglia following to incubation time. Thedata are
means6SEMof three independent experiments. x,p, .001 in comparisonwith control (CON); xx,p, .01; xxx,p, .001 in comparisonwith LPS.
Abbreviations: CON, control; DAPI, 49,6-diamidino-2-phenylindole; hr, hour; LPS, lipopolysaccharide; MFI, mean fluorescence intensity; MSC-
CM, mesenchymal stromal cell-conditioned media; RQ, relative quantity.
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[14, 28, 29, 31], andN9 cell line is different fromprimarymicroglia
culture on microglia signature expression [32]. Thus, we con-
cluded that this discrepancy might be related to potential micro-
glia character, MSC culture condition, and microenvironment.
Our MSC-CM contained sufficient TGF-b (1747 6 29.3 pg/ml)
but had less CX3CL1 (15.9 6 0.1 pg/ml) than that (15 ng/ml) of
the previous study [29]. When the MSC number reached 1.3 3
107 (7 days after 23105MSC seeding), themaximumcell number
in a 75T flask, the CX3CL1 concentration was 477.75 pg/ml, which
was still less than 10 ng/ml (data not shown). Only 1–2 3 106
MSCs have been administered inmost clinical and animal studies,
because it is rare to isolate more than 1–23 106 MSC/kg weight
from adults, andmost studies have shownmaximum efficacy and
negligible mortality at the dose of 13 106 MSCs [20, 23, 25, 33].
Therefore, it seems unlikely that the CX3CL1 concentration in the
CSF would reach 10 ng/ml when 1–2 3 106 MSCs are adminis-
tered intrathecally, although we cannot exclude the possibility
that the primed MSCs in an inflammatory microenvironment
could acquire an immunomodulatory phenotype, enhancing
the release of CX3CL1 and TGF-b, as in previous studies [25,
30]. Collectively, these results suggest that CX3CL1 in our
MSC-CM is not the main contributor to the M2 transition but is
a candidate factor that can also reduce proinflammatory cytokine
expression and rescue the M2 phenotype. In addition, our results
indicate that TGF-b alone in MSC-CM is sufficient to suppress the
inflammatory reaction and restore a M2 microglia phenotype.
Thus, we propose that the amount and quantity of soluble factors
such as TGF-b and CX3CL1may contribute toMSC efficacy in neu-
rodegenerative diseases involving microglia. However, further
study will be required to clarify which soluble factor secreted by
human MSC contributes to the functional properties of human
microglia.
The NF-kB pathway plays a pivotal role in inflammatory reac-
tions, and a recent study has demonstrated that microglia induce
motor neuron death via the classical NF-kB pathway [7]. Classical
NF-kB consists of the p65/p50 heterodimer and is a pivotal
regulator in inflammatory reactions, driving proinflammatory
cytokine gene expression in microglia [34]. TGF-b signaling, a
potent deactivator of microglia, is thought to act as an anti-
inflammatory cytokine [9] and down-regulates cytokine produc-
tion in LPS-stimulated microglia via Smad phosphorylation [35].
The relationship between CX3CL1 (fractalkine) and its receptor
Figure 5. TGF-bR inhibition alone can abolish the effect ofMSC-CM in LPS-stimulatedmicroglia. To investigate whether CX3CL1 plays a role in
the anti-inflammatory effect of TGF-b inMSC-CM,we added a CX3CL1 antibody, a TGF-bR inhibitor, and both together toMSC-CM. LPS reduced
CX3CR1 (A) and increased TNF-amRNA expression (B), IL-1bmRNA expression (C), IL-6 mRNA expression (D), and iNOS mRNA expression (E),
and. MSC-CM rescued these changes. The TGF-bR inhibitor alone showed the same effect on LPS-stimulated microglia, regardless of the pres-
ence of the CX3CL1 antibody. When the TGF-bR inhibitor was added to theMSC-CM, the effect of theMSC-CM on TNF-a, IL-1b, IL-6, iNOS, and
CX3CR1was abolished. The data aremeans6 SEMof three independent experiments. p, p, .05; pp, p, .01; ppp, p, .001; in comparisonwith
control. x, p, .05; xx, p, .01; xxx, p, .001; in comparison with LPS. †, p, .05; †††, p, .001; compared between two groups. Abbreviations:
iNOS, inducible nitric oxide; IL, interleukin; LPS, lipopolysaccharide; MSC-CM,mesenchymal stromal cell-conditionedmedia; RQ, relative quan-
tity; TGF, transforming growth factor; TNF, tumor necrosis factor.
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(CX3CR1) is tightly regulated in the brain. CX3CL1 is known to
modulate a complex network of paracrine and autocrine inter-
actions between neurons and microglia, controlling microglia
neurotoxicity [11]. A recent study showed that activation of
the NF-kB pathway inhibited CX3CR1 expression in microglia
via yy1 and led to attenuated functional responses of microglia
to CX3CL1 [36]. Our results also showed that MSC-CM inhibited
the NF-kB pathway, restored Smad2/3 phosphorylation, and
normalized CX3CR1 expression in LPS-stimulated microglia.
A TGF-bR inhibitor abolished the MSC-CM effects, and siMSC-
CM did not affect the microglia functional phenotype. We con-
clude from these results that MSC-secreted TGF-b restores the
reduced CX3CR1 expression via inhibition of the NF-kB pathway
by TGF-b1R-related Smad2/3 phosphorylation in LPS-induced
microglia. However, further study will be required to confirm
whether TGF-b2 or 3R-related signaling pathways are also in-
volved in microglia functional phenotype.
In the current study, rTGF-bmimics the effect of MSC-CM on
LPS-stimulatedmicroglia. However,MSCs exert a broad spectrum
of immunoregulatory effects on cells of both the innate and adap-
tive immune systems via solublemediators and direct cell contact
[37, 38]. We reported that when MSCs interact with human pe-
ripheral blood mononuclear cell (PBMCs), MSCs were poten-
tiated, and more TGF-b was secreted from both MSCs and
PBMCs, leading to synergic TGF-b elevation in comparison with
MSCs alone [30]. However, rTGF-b in vivo has a short half-life
in its soluble phase, suggesting difficulty in clinical applications
[39]. Furthermore, we cannot ignore the role of various neuro-
tropic factors thatMSCs release. Taken together, we suggest that
MSCs would be superior to rTGF-b in neurodegenerative dis-
eases, although rTGF-b shapes microglial functional effects in
LPS-stimulated microglia.
Although the adult resident microglia phenotype is strictly
controlled in spite of LPS/interferon-g stimulation in healthy
Figure 6. Recombinant TGF-b showed an effect similar to that of MSC-CM on LPS-stimulated microglia. Recombinant TGF-b (rTGF-b,
10 ng/ml) induced similar effects as didMSC-CM.On the basis of a previous study, recombinant CX3CL1 (rCX3CL1, 10 ng/ml) was also tested.
The rTGF-b and rCX3CL1 were applied for 24 hours. rTGF-b rescued the reduced CX3CR1 expression (A) and inhibited the increased
gene expression of TNF-a (B), IL-1b (C), IL-6 (D), and iNOS (E), similar to MSC-CM in LPS-stimulated microglia. rCX3CL1 (10 ng/ml) also
inhibited IL-1b and iNOS expression and restored CX3CR1 expression but did not affect TNF-a and IL-6 expression. The data are means 6
SEM of three independent experiments. p, p , .05; ppp, p , .001; in comparison with control. x, p , .05; xxx, p , .001; in comparison
with LPS. ††, p, .05; †††, p, .001; compared between two groups. Abbreviations: iNOS, inducible nitric oxide; IL, interleukin; LPS, lipo-
polysaccharide;MSC-CM,mesenchymal stromal cell-conditionedmedia; RQ, relative quantity; TGF, transforming growth factor; TNF, tumor
necrosis factor.
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humans [40], a comparison study between blood-derivedmacro-
phages and human adult microglia demonstrated that adult
microglia up-regulate inflammatory markers such as macro-
phages under long-termM1 polarizing conditions [3]. In addition,
most studies demonstrated that M2 phenotype markers, in con-
trast to M1 phenotype markers, could be modulated in adult
microglia, depending on the microenvironment [3, 40]. In sum-
mary, we speculate that MSC-CM could break a chronic in-
flammatory cycle by skewing microglia with disease-specific
characteristics toward anM2 phenotype in various neurodegener-
ative diseases [3, 40, 41]. Whether MSC-CM can switch functional
phenotypes in adult microglia from patients should be clarified.
CONCLUSION
To the best of our knowledge, few studies have investigated the
underlying mechanism of MSC-CM in primary cultured microglia
by focusing on the functional phenotypes, except for a report
demonstrating the role of CX3CL1. In this study, we found
that TGF-b alone sufficiently restored M2 phenotype markers
and suppressed proinflammatory cytokine expression in LPS-
stimulated microglia. These results are in line with our clinical
data [25], showing that TGF-b is a biomarker determining the ef-
ficacy of MSCs administered intrathecally in ALS. Therefore, we
suggest that TGF-b as well as CX3CL1 released byMSCsmodulate
the inflammatory cycle in microglia and enhance the therapeutic
efficacy of MSCs in clinical trials.
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Figure7. MSC-CM inhibits theNF-kBpathway and rescuesCX3CR1expression via theTGF-b signalingpathway in LPS-stimulatedmicroglia. (A):
LPS increased p-IkB expression and reduced CX3CR1 expression and Smad2/3 phosphorylation by Western blot. MSC-CM restored these
changes in LPS-stimulated microglia. However, the effect of MSC-CM was abolished when TGF-bR inhibitor was applied with MSC-CM.
TGF-bR inhibitor alonedid not affect CX3CR1expression, IkB, or Smad2/3phosphorylation in primary culturedmicroglia. Thep-IkB (B),p-smad2
(C), p-smad3 (D), and CX3CR1 (E) expression levels were measured using densitometry. The data are means6 SEM of three independent ex-
periments. p, p, .05, compared with control. x, p, .05; xx, p, .01; xxx, p, .001; in comparison with LPS. †, p, .05; ††, p, .001; compared
between two groups. Abbreviations: CON, control; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; LPS, lipopolysaccharide; MSC-CM,
mesenchymal stromal cell-conditioned media; TGF, transforming growth factor.
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